Novye vozmozhnosti kombinirovannoy terapii arterial'noy gipertenzii: amlodipin + valsartan


Cite item

Full Text

Abstract

Комбинированная терапия артериальной гипертензии (АГ) давно не мода, а необходимость. Действительно, по результатам клинических исследований последних лет, для достижения целевого уровня артериального давления (АД) в среднем требуются 2–3 препарата. Об этом же свидетельствуют и данные реальной клинической практики во всех развитых и развивающихся странах мира. К сожалению, несмотря на признание медицинской общественностью необходимости комбинированной терапии у большинства пациентов с АГ, в особенности у лиц с высоким и очень высоким риском сердечно-сосудистых осложнений, пациентов с сахарным диабетом (СД), метаболическим синдромом, сопутствующими клиническими состояниями, частота достижения целевого уровня АД остается невысокой.Одним из наиболее эффективных методов улучшения контроля АГ является использование комбинированной антигипертензивной терапии. Первая фиксированная комбинация АК амлодипина и БРА валсартана (препарат Эксфорж, «Новартис Фарма», Швейцария) обеспечивает воздействие на два ключевых механизма повышения АД – вызывает мощную вазодилатацию и контролирует повышенную активность РААС.

About the authors

V. I Podzolkov

ММА им. И.М.Сеченова

Кафедра факультетской терапии №2 лечебного факультета

References

  1. Wolf-Maier K, Cooper R.S, Kramer H et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10–7.
  2. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 60: 45–50.
  3. Okonofua E.C, Simpson K.N, Jesri A et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006; 47: 345–51.
  4. Franklin S.S. Hypertension in older people: part 1. J Clin Hypertens (Greenwich) 2006; 8: 444–9.
  5. Franklin S.S. Hypertension in older people: part 2. J Clin Hypertens (Greenwich) 2006; 8: 521–5.
  6. Mancia G, De Backer G, Dominiczak A et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87.
  7. Kjeldsen S.E, Aksnes T.A, de la Sierra A, Ruilope L.M. Amlodipine and valsartan: calcium channel blockers/angiotensin II receptor blockers combination for hypertension. Therapy 2007; 4: 31–40.
  8. van Zweit P.A. Calcium antagonists as antihypertensives. In Oparil S, Weber M.A (eds): Hypertension: a companion to Brenner and Rector's the Kidney, Edition Philadelphia: Saunders Company 2000; 389–98.
  9. Schmieder R.E, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta - analysis of randomized double - blind studies. Jama 1996; 275: 1507–13.
  10. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95–110.
  11. Epstein M. Calcium antagonists and the kidney: implications for renal protection. In Epstein M (ed) Calcium antagonists in clinical medicine. Philadelphia: Hanley & Belfus, Inc. 1998; 433–65.
  12. Kloke H.J, Branten A.J, Huysmans F.T, Wetzels J.F. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int 1998; 53: 1559–73.
  13. Dahlof B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
  14. Mutlu H, Ozhan H, Okcun B et al. The Efficacy of Valsartan in Essential Hypertension and its Effects on Left Ventricular Hypertrophy. Blood Pressure 2002; 11: 53–5.
  15. Klingbeil A.U, Schneider M, Martus P et al. A meta - analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41–6.
  16. Wong M, Staszewsky L, Latini R et al. Valsartan benefits left ventricular structure and function in heart failure: Val - HeFT echocardiographic study. J Am Coll Cardiol 2002; 40: 970–5.
  17. Pfeffer M.A, Mc Murray J.J, Velazquez E.J et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.
  18. Viberti G, Wheeldon N.M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure - independent effect. Circulation 2002; 106: 672–8.
  19. Hollenberg N.K, Parving H.H, Viberti G et al. Albuminuria response to very high - dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921–6.
  20. Atkins R.C, Briganti E.M, Lewis J.B. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281–7.
  21. Brenner B.M, Cooper M.E, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.
  22. Schrader J, Luders S, Kulschewski A et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218–26.
  23. Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open - label, blinded endpoint morbidity - mortality study. Lancet 2007; 369: 1431–9.
  24. Подзолков В.И., Булатов В.А., Сон Е.А. Антагонисты АТ1 - рецепторов и состояние микроциркуляции у больных гипертонической болезнью: еще одна мишень для терапии? Клинич. фармакол. и тер. 2005; 14: 41–6.
  25. Podzolkov V.I, Bulatov V.A, Son E.A, Os I. Central and peripheral hemodynamic effects of losartan and in combination with hydrochlorothiazide in mild to moderate essential hypertension. Blood Press 2003; 12: 239–45.
  26. Elliott W.J, Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta - analysis. 2007; 369: 201–7.
  27. Dahlof B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
  28. Top C, Cingozbay B.Y, Terekeci H et al. The effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res 2002; 30: 15–20.
  29. Hanefeld M, Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res 2001; 29: 270–9.
  30. Kjeldsen S.E, Julius S, Mancia G et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high - risk hypertensive patients: the VALUE trial. J Hypertens 2006; 24: 1405–12.
  31. Weycker D, Edelsberg J, Vincze G et al. Risk of diabetes in a real - world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. J Hum Hypertens 2007; 21: 374–80.
  32. Clavijo G.A, de Clavijo I.V, Weart C.W. Amlodipine: a new calcium antagonist. Am J Hosp Pharm 1994; 51: 59–68.
  33. Pitt B, Byington R.P, Furberg C.D et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
  34. Nissen S.E, Tuzcu E.M, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–25.
  35. Leenen F.H, Nwachuku C.E, Black H.R et al. Clinical events in high - risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin - converting enzyme inhibitor in the antihypertensive and lipid - lowering treatment to prevent heart attack trial. Hypertension 2006; 48: 374–84.
  36. Williams B, Lacy P.S, Thom S.M et al. Differential impact of blood pressure - lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
  37. Fogari R, Preti P, Derosa G et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002; 58: 177–80.
  38. Fogari R, Zoppi A, Poletti L et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14: 27–31.
  39. Fogari R, Preti P, Zoppi A et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens 2004; 17: 77–81.
  40. Bloom B.S. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671–81.
  41. Thurmann P.A, Kenedi P, Schmidt A et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037–42.
  42. Peters S, Gotting B, Trummel M et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL - PREST trial. J Invasive Cardiol 2001; 13: 93–7.
  43. Peters S, Trummel M, Meyners W et al. Valsartan versus ACE inhibition after bare metal stent implantation – results of the VALVACE trial. Int J Cardiol 2005; 98: 331–5.
  44. Schmieder R, Hua T. Reduced Incidence of New Onset Atrial Fibrillation with Angiotensin II Receptor Blockade: The VALUE-Trial. J Hypertens 2006; 24 (Suppl.): S3.
  45. Maggioni A.P, Latini R, Carson P.E et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548–57.
  46. Weycker D, Falvey H, Edelsberg J, Oster J. Risk of diabetes in hypertensive patients receiving valsartan versus losartan. J Clin Hypertens 2007; Suppl. A (9): 448.
  47. Cohn J.N, Tognoni G. A randomized trial of the angiotensin - receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–75.
  48. Philipp T, Smith T.R, Glazer R et al. Two multicenter, 8-week, randomized, double - blind, placebo - controlled, parallel - group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29: 563–80.
  49. Smith T.R, Philipp T, Vaisse B et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo - controlled studies. J Clin Hypertens (Greenwich) 2007; 9: 355–64.
  50. Poldermans D, Glazes R, Kargiannis S et al. Tolerability and blood pressure - lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007; 29: 279–89.
  51. Allemann Y, Fraile B, Lambert M et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure After Single Therapy (EX-FAST) Study. J Clin Hypertens 2008; 10.
  52. Fogari R, Zoppi A, Derosa G et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007; 21: 220–4.
  53. Messerli F.H. Vasodilatory edema: a common side effect of antihypertensive therapy. Am J Hypertens 2001; 14: 978–9.

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies